Bioxytran annual debt-to-assets ratio
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bioxytran's debt-to-assets ratio was 1.22 for fiscal 2025.
View full Bioxytran company overview| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.22 | −4.58 | −78.94% |
| 2024 | 2024-12-31 | 5.80 | −7.83 | −57.42% |
| 2023 | 2023-12-31 | 13.63 | 7.80 | +133.55% |
| 2022 | 2022-12-31 | 5.84 | −11.95 | −67.19% |
| 2021 | 2021-12-31 | 17.79 | 12.85 | +260.14% |
| 2020 | 2020-12-31 | 4.94 | 1.07 | +27.49% |
| 2019 | 2019-12-31 | 3.87 | −2.37 | −37.95% |
| 2018 | 2018-12-31 | 6.24 | 6.21 | +18026.49% |
| 2017 | 2017-12-31 | 0.03 | — | — |
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.41 | −3.04 | −55.76% |
| Q1 2026 | 2026-03-31 | 1.31 | −4.61 | −77.89% |
| Q4 2025 | 2025-12-31 | 1.22 | −4.58 | −78.94% |
| Q3 2025 | 2025-09-30 | 5.15 | 0.09 | +1.74% |
| Q2 2025 | 2025-06-30 | 5.46 | −0.22 | −3.89% |
| Q1 2025 | 2025-03-31 | 5.92 | −0.95 | −13.78% |
| Q4 2024 | 2024-12-31 | 5.80 | −7.83 | −57.42% |
| Q3 2024 | 2024-09-30 | 5.06 | −4.99 | −49.63% |
| Q2 2024 | 2024-06-30 | 5.68 | −8.30 | −59.38% |
| Q1 2024 | 2024-03-31 | 6.86 | −2.41 | −25.98% |
| Q4 2023 | 2023-12-31 | 13.63 | 7.80 | +133.55% |
| Q3 2023 | 2023-09-30 | 10.05 | 5.24 | +108.95% |
| Q2 2023 | 2023-06-30 | 13.98 | 7.66 | +121.05% |
| Q1 2023 | 2023-03-31 | 9.27 | 4.87 | +110.85% |
| Q4 2022 | 2022-12-31 | 5.84 | −11.95 | −67.19% |
| Q3 2022 | 2022-09-30 | 4.81 | 3.38 | +235.69% |
| Q2 2022 | 2022-06-30 | 6.32 | 5.15 | +439.58% |
| Q1 2022 | 2022-03-31 | 4.40 | 0.21 | +5.07% |
| Q4 2021 | 2021-12-31 | 17.79 | 12.85 | +260.14% |
| Q3 2021 | 2021-09-30 | 1.43 | −2,533.88 | −99.94% |
| Q2 2021 | 2021-06-30 | 1.17 | −376.80 | −99.69% |
| Q1 2021 | 2021-03-31 | 4.18 | −34.97 | −89.31% |
| Q4 2020 | 2020-12-31 | 4.94 | 1.07 | +27.49% |
| Q3 2020 | 2020-09-30 | 2,535.32 | 2,517.58 | +14195.17% |
| Q2 2020 | 2020-06-30 | 377.97 | 363.98 | +2602.75% |
| Q1 2020 | 2020-03-31 | 39.16 | 32.91 | +527.06% |
| Q4 2019 | 2019-12-31 | 3.87 | −2.37 | −37.95% |
| Q3 2019 | 2019-09-30 | 17.74 | — | — |
| Q2 2019 | 2019-06-30 | 13.98 | 13.95 | +38285.40% |
| Q1 2019 | 2019-03-31 | 6.24 | 6.21 | +17178.02% |
| Q4 2018 | 2018-12-31 | 6.24 | 6.21 | +18026.49% |
| Q2 2018 | 2018-06-30 | 0.04 | — | — |
| Q1 2018 | 2018-03-31 | 0.04 | — | — |
| Q4 2017 | 2017-12-31 | 0.03 | — | — |
Over the last five fiscal years, Bioxytran's debt-to-assets ratio decreased from 4.94 to 1.22, a change of −3.72. The latest reported quarter, Q2 2026, shows 2.41.
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioxytran source filings ↗